Key Points
- LivaNova director Francesco Bianchi sold 1,800 shares at an average price of $75.75, totaling $136,350. After the sale, he still held 7,228 shares, a nearly 20% reduction in his position.
- The stock was trading near its 52-week high at $73.90, and it was down 2.0% on the day of the report. LivaNova’s shares have ranged from $41.01 to $75.82 over the past year.
- Recent earnings topped expectations, with quarterly EPS of $0.98 versus the $0.85 consensus and revenue up 14.3% year over year. Analysts currently have a “Moderate Buy” consensus with an average price target of $79.38.
LivaNova PLC (NASDAQ:LIVN - Get Free Report) Director Francesco Bianchi sold 1,800 shares of the business's stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director directly owned 7,228 shares in the company, valued at approximately $547,521. This represents a 19.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
LivaNova Stock Down 2.0%
NASDAQ:LIVN opened at $73.90 on Thursday. The company has a market cap of $4.06 billion, a PE ratio of 37.90 and a beta of 0.82. LivaNova PLC has a twelve month low of $41.01 and a twelve month high of $75.82. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The company's 50 day moving average is $66.16 and its two-hundred day moving average is $64.05.
LivaNova (NASDAQ:LIVN - Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.13. The company had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. LivaNova's revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Analysts anticipate that LivaNova PLC will post 3.72 EPS for the current year.
Analyst Ratings Changes
Several analysts have weighed in on the stock. Weiss Ratings raised shares of LivaNova from a "sell (d+)" rating to a "hold (c)" rating in a research report on Thursday, May 7th. Barclays boosted their target price on shares of LivaNova from $73.00 to $76.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 7th. Needham & Company LLC boosted their target price on shares of LivaNova from $64.00 to $81.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Mizuho boosted their target price on shares of LivaNova from $85.00 to $90.00 and gave the stock an "outperform" rating in a research report on Thursday, May 7th. Finally, Robert W. Baird dropped their target price on shares of LivaNova from $78.00 to $76.00 and set an "outperform" rating on the stock in a research report on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $79.38.
Check Out Our Latest Stock Report on LIVN
Hedge Funds Weigh In On LivaNova
Institutional investors have recently modified their holdings of the stock. Envestnet Asset Management Inc. raised its stake in shares of LivaNova by 168.1% during the 3rd quarter. Envestnet Asset Management Inc. now owns 27,125 shares of the company's stock valued at $1,421,000 after buying an additional 17,007 shares during the last quarter. Allianz Asset Management GmbH purchased a new position in shares of LivaNova during the 3rd quarter valued at about $7,687,000. LSV Asset Management raised its stake in shares of LivaNova by 25.4% during the 3rd quarter. LSV Asset Management now owns 674,610 shares of the company's stock valued at $35,336,000 after buying an additional 136,600 shares during the last quarter. Boone Capital Management LLC purchased a new position in shares of LivaNova during the 3rd quarter valued at about $8,796,000. Finally, Rock Point Advisors LLC purchased a new position in shares of LivaNova during the 3rd quarter valued at about $3,066,000. Hedge funds and other institutional investors own 97.64% of the company's stock.
LivaNova Company Profile
(
Get Free Report)
LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.
The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
